In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics.
暂无分享,去创建一个
[1] Beverly S Mitchell,et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Darnell. Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.
[3] R. Orlowski,et al. NF-?B as a therapeutic target in cancer , 2002 .
[4] N. Munshi,et al. NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.
[5] S. Alkan,et al. Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis , 2001 .
[6] E. Sausville,et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.
[7] D. Lauffenburger,et al. Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. , 2003, Molecular pharmacology.
[8] A. Hoffmann,et al. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. , 2002, Science.
[9] B. Aggarwal,et al. Nuclear transcription factor-kappaB as a target for cancer drug development. , 2002, Leukemia.
[10] A Garg,et al. Nuclear transcription factor-κB as a target for cancer drug development , 2002, Leukemia.
[11] R. Orlowski,et al. NF-kappaB as a therapeutic target in cancer. , 2002, Trends in molecular medicine.
[12] S. Alkan,et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. , 2001, British journal of haematology.
[13] H. Pahl,et al. Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.
[14] A. Hoffmann,et al. The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .